+919405117673

Oncology Medicine

Venclexta (Venetoclax) Tablets 50 mg & 100 mg: Uses, Dosage, Side Effects and Safety

In stock

Description

Prescription-only medicine. For general information only.

Overview

Venclexta (venetoclax) is an oral targeted therapy in the BCL-2 inhibitor class. It is prescribed by specialists as part of treatment regimens for certain blood cancers. Tablets are available in several strengths, including 50 mg and 100 mg. The prescriber decides the strength, number of tablets and schedule for each patient.

Product details

Brand / generic name Venclexta / Venetoclax

Drug class BCL-2 inhibitor (targeted anticancer therapy)

Dosage form and route Film-coated tablets, oral

Strengths including 50 mg, 100 mg

Marketing authorisation holder AbbVie [confirm against the product shown]

Pack size 28 Tablets per Box

Legal status Prescription-only medicine

What is Venclexta used for?

Depending on the approved product information in each country, venetoclax is used in adults with:

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), alone or with other medicines.

Newly diagnosed acute myeloid leukaemia (AML), combined with azacitidine, decitabine or low-dose cytarabine, for patients who cannot have intensive chemotherapy.

Approved uses vary between countries and over time. Only a specialist can decide whether this medicine is suitable for a particular patient.

How does venetoclax work?

Some blood cancer cells rely on a protein called BCL-2 to survive. Venetoclax blocks this protein, which allows susceptible cancer cells to die naturally.

Dosage and administration

Take Venclexta exactly as prescribed. The dose depends on the condition being treated, any combination medicines, blood test results and the individual patient. The product information directs patients to swallow tablets whole, with food and water, at about the same time each day. Some treatment plans begin with a gradual dose increase over several weeks to reduce the risk of tumour lysis syndrome (TLS). Never change or stop your dose without medical advice.

Possible side effects

Common side effects include low white blood cell counts, anaemia, low platelet counts, nausea, vomiting, diarrhoea, constipation, fatigue, fever and upper respiratory infections. Serious risks include tumour lysis syndrome and severe infections. Seek urgent medical help for fever, passing little or no urine, confusion, severe weakness, muscle cramps or an irregular heartbeat. In India, suspected adverse reactions can be reported through the Pharmacovigilance Programme of India (PvPI); ask your doctor or pharmacist how to report.

Important warnings and precautions

Tumour lysis syndrome: rapid breakdown of cancer cells can cause serious blood-chemistry and kidney problems. Blood tests, hydration and preventive medicines are essential.

Infections and low blood counts: blood counts should be monitored, and signs of infection need prompt review.

Interactions: medicines that affect CYP3A or P-glycoprotein can change venetoclax levels. Grapefruit, Seville oranges and starfruit should generally be avoided. Tell your doctor about all medicines and supplements, including herbal products.

Vaccines: ask your care team before having any live vaccine.

Pregnancy and breastfeeding: venetoclax can harm an unborn baby. Follow the guidance in the approved product information.

Frequently asked questions

Is Venclexta a chemotherapy medicine?

No. It is a targeted therapy that blocks the BCL-2 protein, although it is sometimes combined with chemotherapy-type medicines.

What is the difference between the 50 mg and 100 mg tablets?

They contain different amounts of venetoclax. The specialist decides which strengths and how many tablets are needed.

Can Venclexta be used without a prescription?

No. It must be used under the supervision of a qualified specialist.

Medical disclaimer

This page provides general information only and is not medical advice. It does not replace the approved product information or the advice of your specialist.

Published by Cordium Pharmaceuticals Pvt. Ltd., Nagpur, India. Last reviewed: 18 Nov 2026 | Reviewed by: Ghanshyam Dehari Senior Pharmacist | Source: https://www.venclexta.com/

Keywords